Evaluation of the effect of fluconazole on the pharmacokinetics of ritonavir

Drug Metabolism and Disposition

Volumn 25, Issue 9, 1997, Pages 1104-1106

  Cato III, Allen ^a   Cao, Guoliang ^b   Hsu, Ann ^b   Cavanaugh, John ^b   Leonard, John ^b   Granneman, Richard ^b  

^a ABBOTT LABORATORIES   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

FLUCONAZOLE; PROTEINASE INHIBITOR; RITONAVIR;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; AREA UNDER THE CURVE; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DRUG BLOOD LEVEL; DRUG EFFECT; DRUG SCREENING; FEMALE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MALE; MYCOSIS; NAUSEA; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; VOMITING;

ADULT; ANTIFUNGAL AGENTS; AREA UNDER CURVE; CROSS-OVER STUDIES; DRUG INTERACTIONS; FEMALE; FLUCONAZOLE; HIV PROTEASE INHIBITORS; HUMANS; MALE; METABOLIC CLEARANCE RATE; RITONAVIR;

HUMAN IMMUNODEFICIENCY VIRUS;

EID: 0030766424     PISSN: 00909556     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (19)

1. R. B. Pollard: Use of proteinase inhibitors in clinical practice. Pharmacotherapy 14, 21S-29S (1994).
2. D. J. Kempf, K. C. Marsh, J. F. Denissen, E. McDonald, S. Vasavanonda, C. A. Flentge, B. E. Green, A. Hsu, J. J. Plattner, J. M. Leonard, and D. W. Norbeck: ABT-538 is a potent inhibitor of human immunodeficiency virus protease and has high oral bioavailability in humans. Proc. Natl. Acad. Sci. U.S.A. 92, 2484-2488 (1995).
3. M. Markowitz, M. Saag, W. G. Powderly, A. M. Hurley, A. Hsu, J. M. Valdes, D. Henry, J. M. Leonard, D. D. Ho, et al.: A preliminary study of ritonavir, an inhibitor of HIV-1 protease, to treat HIV-1 infection. N. Engl. J. Med. 333, 1534-1539 (1995).
4. S. A. Danner, A. Carr, J. M. Leonard, L. M. Lehman, F. Gudiol, J. Gonzales, A. Hsu, J. M. Valdes, et al.: A short-term study of the safety, pharmacokinetics, and efficacy of ritonavir, an inhibitor of HIV-1 protease. N. Engl. J. Med. 333, 1528-1533 (1995).
5. D. D. Ho, A. U. Neumann, A. S. Perelson, W. Chen, J. M. Leonard, and M. Markowitz: Rapid turnover of plasma virions and CD4 lymphocytes in HIV-1 infection. Nature 373, 123-126 (1995).
6. G. P. Body: Azole antifungal agents. Clin. Infect. Dis. 14, S161-S169 (1992).
7. K. Richardson, K. Cooper, M. S. Marriott, M. H. Tarbit, P. F. Troke, and P. J. Whittle: Discovery of fluconazole, a novel antifungal agent. Rev. Infect. Dis. 12, S267-S271 (1990).
8. M. Maurice, L. Pichard, M. Daujat, I. Fabre, H. Joyeux, J. Domergue, and P. Maurel: Effects of imidazole derivatives on cytochromes P450 from human hepatocytes in primary culture. FASEB J. 6, 752-758 (1992).
9. J. D. Lazar and K. D. Wilner: Drug interactions with fluconazole. Rev. Infect. Dis. 12, S327-S333 (1990).
10. P. K. Honig, D. C. Wortham, K. Zamani, J. C. Mullin, D. P. Conner, and L. R. Cantilena: The effect of fluconazole on the steady-state pharmacokinetics and electrocardiographic pharmacodynamics of terfenadine in humans. Clin. Pharmacol. Ther. 53, 630-636 (1993).
11. M. Jurima-Romet, K. Crawford, T. Cyr, and T. Inaba: Terfenadine metabolism in human liver. In vitro inhibition by macrolide antibiotics and azole antifungals. Drug Metab. Dispos. 22, 849-857 (1994).
12. K. R. Gericke: Possible interaction between warfarin and fluconazole. Pharmacatherapy 13, 508-509 (1993).
13. R. M. Cadle, G. J. Zenon III, M. C. Rodriguez-Barradas, and R. J. Hamill: Fluconazole-induced symptomatic phenytoin toxicity. Ann. Pharmacother. 28, 191-195 (1994).
14. J. A. J. Barbara, A. R. Clarkson, J. LaBrooy, J. D. McNeil, and A. J. Woodroffe: Candida albicans arthritis in a renal allograft recipient with an interaction between cyclosporin and fluconazole. Nephrol. Dial. Transpl. 8, 263-266 (1993).
15. K. L. Kunze, L. C. Wienkers, K. E. Thummel, and W. F. Trager: Wartarinfluconazole. I. Inhibition of the human cytochrome P450-dependent metabolism of warfarin by fluconazole: in vitro studies. Drug Metab. Dispos. 24, 414-421 (1996).
16. G. N. Kumar, A. D. Rodrigues, A. M. Buko, and J. F. Denissen: Cytochrome P450-mediated metabolism of the HIV-1 protease inhibitor ritonavir (ABT-538) in human liver microsomes. J. Pharmacol. Exp. Ther. 277, 423-431 (1996).
17. D. Debruyne and J.-P. Ryckelynck: Clinical pharmacokinetics of fluconazole. Clin. Pharmacokinet. 24, 10-27 (1993).
18. Abbott Laboratories: Package insert, Norvir, Abbott Laboratories, North Chicago, IL, March 1996.
19. Roerig: Package insert, Diflucan, Roerig, New York, NY, January 1994.